Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Range-Finding Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Adult and Adolescent Patients (12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.

Study Overview

• Status: Completed
• Conditions: Seasonal Allergic Rhinitis; Hayfever
• Intervention / Treatment: Drug: Beclomethasone dipropionate HFA Nasal Aerosol; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 487
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Mission Viejo, California, United States, 92691
      • Teva Global Respiratory Research Study Site
    • San Diego, California, United States, 92120
      • Teva Global Respiratory Research Study Site
    • San Diego, California, United States, 92123
      • Teva Global Respiratory Research Study Site
  • Colorado
    • Colorado Springs, Colorado, United States, 08907
      • Teva Global Respiratory Research Study Site
    • Denver, Colorado, United States, 08230
      • Teva Global Respiratory Research Study Site
  • Georgia
    • Gainesville, Georgia, United States, 030501
      • Teva Global Respiratory Research Study Site
    • Savannah, Georgia, United States, 31406
      • Teva Global Respiratory Research Study Site
  • Indiana
    • Indianapolis, Indiana, United States, 46208
      • Teva Global Respiratory Research Study Site
  • Kansas
    • Overland Park, Kansas, United States, 66210
      • Teva Global Respiratory Research Study Site
  • Maryland
    • Bethesda, Maryland, United States, 20814
      • Teva Global Respiratory Research Study Site
  • Missouri
    • St. Louis, Missouri, United States, 63141
      • Teva Global Respiratory Research Study Site
  • New Jersey
    • Brick, New Jersey, United States, 08724
      • Teva Global Respiratory Research Study Site
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • Teva Global Respiratory Research Study Site
  • Oregon
    • Medford, Oregon, United States, 97504
      • Teva Global Respiratory Research Study Site
    • Portland, Oregon, United States, 97213
      • Teva Global Respiratory Research Study Site
  • Pennsylvania
    • Blue Bell, Pennsylvania, United States, 19422
      • Teva Global Respiratory Research Study Site
    • Pittsburgh, Pennsylvania, United States, 15241
      • Teva Global Respiratory Research Study Site
    • Upland, Pennsylvania, United States, 19013
      • Teva Global Respiratory Research Study Site
  • South Carolina
    • Charleston, South Carolina, United States, 29407
      • Teva Global Respiratory Research Study Site
  • Texas
    • Austin, Texas, United States, 78713
      • Teva Global Respiratory Research Study Site
    • Dallas, Texas, United States, 75231
      • Teva Global Respiratory Research Study Site
    • New Braunfels, Texas, United States, 78130
      • Teva Global Respiratory Research Study Site
    • San Antonio, Texas, United States, 78229
      • Teva Global Respiratory Research Study Site
  • Utah
    • Draper, Utah, United States, 84020
      • Teva Global Respiratory Research Study Site
  • Virginia
    • Burke, Virginia, United States, 22015
      • Teva Global Respiratory Research Study Site
    • Richmond, Virginia, United States, 23233
      • Teva Global Respiratory Research Study Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Male or female patients 12 years of age and older, as of the Screening Visit (SV).
• General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study.
• A history of SAR to relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV). The SAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past and in the investigator's judgment is expected to be exposed to the allergen and require treatment throughout the entire study period.
• A demonstrated sensitivity to relevant tree/grass pollen known to produce SAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the skin prick test. Documentation of a positive result within 12 months prior to Screening Visit (SV) is acceptable.
• Other criteria apply

Key Exclusion Criteria:

• Participation in any investigational drug study within the 30 days preceding the Screening Visit (SV) or planned participation in another investigational drug study at any time during this study.
• History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the SV).
• History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.
• Use of any prohibited concomitant medications within the prescribed (per protocol) time since the last dosing period prior to the Screening Visit (SV) and/or plans for use during the entire treatment duration.
• Other criteria apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BDP HFA 80 µg/day; During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.	Drug: Beclomethasone dipropionate HFA Nasal Aerosol; Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol; Other Names: QNASL(TM); Drug: Placebo; HFA Vehicle Aerosol
Experimental: BDP HFA 160 µg/day; During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.	Drug: Beclomethasone dipropionate HFA Nasal Aerosol; Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol; Other Names: QNASL(TM)
Experimental: BDP HFA 320 µg/day; During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.	Drug: Beclomethasone dipropionate HFA Nasal Aerosol; Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol; Other Names: QNASL(TM)
Placebo Comparator: Placebo; During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.	Drug: Placebo; HFA Vehicle Aerosol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period	Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM & PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period	Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM & PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period	Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)	The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.	Baseline and Week 2
Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period	Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping). The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period	Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping). Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

Collaborators and Investigators

• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
• Investigators: Study Chair: Sudeesh Tantry, Ph.D., Teva Branded Pharmaceutical Products R&D, Inc.

Publications and helpful links

General Publications

• Raphael GD, Berger WE, Prenner BM, Finn AF Jr, Kelley L, Tantry SK. Efficacy, safety, and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med Res Opin. 2013 Oct;29(10):1329-40. doi: 10.1185/03007995.2013.821055. Epub 2013 Aug 6.

Study record dates

Study Major Dates

• Study Start: March 1, 2009
• Primary Completion (Actual): May 1, 2009
• Study Completion (Actual): May 1, 2009

Study Registration Dates

• First Submitted: March 2, 2009
• First Submitted That Met QC Criteria: March 2, 2009
• First Posted (Estimate): March 3, 2009

Study Record Updates

• Last Update Posted (Estimate): May 22, 2012
• Last Update Submitted That Met QC Criteria: April 23, 2012
• Last Verified: April 1, 2012

More Information

Terms related to this study

• Keywords: Hayfever; Seasonal Allergic Rhinitis
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Immune System Diseases; Hypersensitivity, Immediate; Otorhinolaryngologic Diseases; Respiratory Hypersensitivity; Hypersensitivity; Nose Diseases; Rhinitis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Physiological Effects of Drugs; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Anti-Asthmatic Agents; Respiratory System Agents; Beclomethasone
• Other Study ID Numbers: BDP-AR-201